drugset / Trial / NCT01510158
Combining Lesinurad With Allopurinol in Inadequate Responders
RandomizedParallel-groupDouble-blindTreatment
Summary
This study that compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to allopurinol.
Timeline
- Start
- 2012-01
- Primary completion
- 2014-07
- Completion
- 2014-08
Publications
- Topless R, Noorbaloochi S, Merriman TR, Singh JA. Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout. Semin Arthritis Rheum. 2022 Oct;56:152057. doi: 10.1016/j.semarthrit.2022.152057. Epub 2022 Jun 29.
- Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis Rheumatol. 2017 Jan;69(1):203-212. doi: 10.1002/art.39840.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lesinurad | Small molecule | 200 mg | Oral |
| Subject | Lesinurad | Small molecule | 400 mg | Oral |
| Comparator | Allopurinol | Small molecule | 200 mg | — |
| Comparator | Allopurinol | Small molecule | 300 mg | — |